Chinese Medical Journal最新文献

筛选
英文 中文
Landscape of respiratory syncytial virus. 呼吸道合胞病毒的分布。
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003354
Yuping Duan, Zimeng Liu, Na Zang, Bingbing Cong, Yuqing Shi, Lili Xu, Mingyue Jiang, Peixin Wang, Jing Zou, Han Zhang, Ziheng Feng, Luzhao Feng, Lili Ren, Enmei Liu, You Li, Yan Zhang, Zhengde Xie
{"title":"Landscape of respiratory syncytial virus.","authors":"Yuping Duan, Zimeng Liu, Na Zang, Bingbing Cong, Yuqing Shi, Lili Xu, Mingyue Jiang, Peixin Wang, Jing Zou, Han Zhang, Ziheng Feng, Luzhao Feng, Lili Ren, Enmei Liu, You Li, Yan Zhang, Zhengde Xie","doi":"10.1097/CM9.0000000000003354","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003354","url":null,"abstract":"<p><strong>Abstract: </strong>Respiratory syncytial virus (RSV) is an enveloped, negative-sense, single-stranded RNA virus of the Orthopneumovirus genus of the Pneumoviridae family in the order Mononegavirales. RSV can cause acute upper and lower respiratory tract infections, sometimes with extrapulmonary complications. The disease burden of RSV infection is enormous, mainly affecting infants and older adults aged 75 years or above. Currently, treatment options for RSV are largely supportive. Prevention strategies remain a critical focus, with efforts centered on vaccine development and the use of prophylactic monoclonal antibodies. To date, three RSV vaccines have been approved for active immunization among individuals aged 60 and above. For children who are not eligible for these vaccines, passive immunization is recommended. A newly approved prophylactic monoclonal antibody, Nirsevimab, which offers enhanced neutralizing activity and an extended half-life, provides exceptional protection for high-risk infants and young children. This review provides a comprehensive and detailed exploration of RSV's virology, immunology, pathogenesis, epidemiology, clinical manifestations, treatment options, and prevention strategies.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impacts of Helicobacter pylori infection and eradication on gastrointestinal microbiota: An up-to-date critical review and future perspectives. 幽门螺杆菌感染和根除对胃肠道微生物群的影响:最新评论和未来展望。
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003348
Yu Li, Cong He, Nonghua Lu
{"title":"Impacts of Helicobacter pylori infection and eradication on gastrointestinal microbiota: An up-to-date critical review and future perspectives.","authors":"Yu Li, Cong He, Nonghua Lu","doi":"10.1097/CM9.0000000000003348","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003348","url":null,"abstract":"<p><strong>Abstract: </strong>Helicobacter pylori (H. pylori) infects approximately half of the population worldwide and causes chronic gastritis, peptic ulcers, and gastric cancer. Test-and-treat strategies have been recommended for the prevention of H. pylori-associated diseases. Advancements in high-throughput sequencing technologies have broadened our understanding of the complex gastrointestinal (GI) microbiota and its role in maintaining host homeostasis. Recently, an increasing number of studies have indicated that the colonization of H. pylori induces dramatic alterations in the gastric microbiota, with a predominance of H. pylori and a reduction in microbial diversity. Dysbiosis of the gut microbiome has also been observed after H. pylori infection, which may play a role in the development of colorectal cancer. However, there is concern regarding the impact of antibiotics on the gut microbiota during H. pylori eradication. In this review, we summarize the current literature concerning how H. pylori infection reshapes the GI microbiota and the underlying mechanisms, including changes in the gastric environment, immune responses, and persistent inflammation. Additionally, the impacts of H. pylori eradication on GI microbial homeostasis and the use of probiotics as adjuvant therapy are also discussed. The shifts in the GI microbiota and their crosstalk with H. pylori may provide potential targets for H. pylori-related gastric diseases and extragastric manifestations.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An assessment model for the efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk. 自体 CD19 嵌合抗原受体 T 细胞疗法疗效与复发或难治性弥漫大 B 细胞淋巴瘤风险的评估模型。
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003343
Bin Xue, Yifan Liu, Min Zhang, Gangfeng Xiao, Xiu Luo, Lili Zhou, Shiguang Ye, Yan Lu, Wenbin Qian, Li Wang, Ping Li, Aibin Liang
{"title":"An assessment model for the efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk.","authors":"Bin Xue, Yifan Liu, Min Zhang, Gangfeng Xiao, Xiu Luo, Lili Zhou, Shiguang Ye, Yan Lu, Wenbin Qian, Li Wang, Ping Li, Aibin Liang","doi":"10.1097/CM9.0000000000003343","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003343","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142580991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic management of early esophageal cancer in patients with concomitant cirrhosis. 对合并肝硬化的早期食管癌患者进行内镜治疗。
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003334
Zhenming Zhang, Linlin Zhu
{"title":"Endoscopic management of early esophageal cancer in patients with concomitant cirrhosis.","authors":"Zhenming Zhang, Linlin Zhu","doi":"10.1097/CM9.0000000000003334","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003334","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of Angong Niuhuang Pills in patients with moderate-to-severe acute ischemic stroke (ANGONG TRIAL): A randomized double-blind placebo-controlled pilot clinical trial. 中重度急性缺血性脑卒中患者服用安宫牛黄丸的安全性和有效性(ANGONG TRIAL):随机双盲安慰剂对照试点临床试验。
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003133
Shengde Li, Anxin Wang, Lin Shi, Qin Liu, Xiaoling Guo, Kun Liu, Xiaoli Wang, Jie Li, Jianming Zhu, QiuYi Wu, QingCheng Yang, Xianbo Zhuang, Hui You, Feng Feng, Yishan Luo, Huiling Li, Jun Ni, Bin Peng
{"title":"Safety and efficacy of Angong Niuhuang Pills in patients with moderate-to-severe acute ischemic stroke (ANGONG TRIAL): A randomized double-blind placebo-controlled pilot clinical trial.","authors":"Shengde Li, Anxin Wang, Lin Shi, Qin Liu, Xiaoling Guo, Kun Liu, Xiaoli Wang, Jie Li, Jianming Zhu, QiuYi Wu, QingCheng Yang, Xianbo Zhuang, Hui You, Feng Feng, Yishan Luo, Huiling Li, Jun Ni, Bin Peng","doi":"10.1097/CM9.0000000000003133","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003133","url":null,"abstract":"<p><strong>Background: </strong>Preclinical studies have indicated that Angong Niuhuang Pills (ANP) reduce cerebral infarct and edema volumes. This study aimed to investigate whether ANP safely reduces cerebral infarct and edema volumes in patients with moderate to severe acute ischemic stroke.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled pilot trial included patients with acute ischemic stroke with National Institutes of Health Stroke Scale (NIHSS) scores ranging from 10 to 20 in 17 centers in China between April 2021 and July 2022. Patients were allocated within 36 h after onset via block randomization to receive ANP or placebo (3 g/day for 5 days). The primary outcomes were changes in cerebral infarct and edema volumes after 14 days of treatment. The primary safety outcome was severe adverse events (SAEs) for 90 days.</p><p><strong>Results: </strong>There were 57 and 60 patients in the ANP and placebo groups finally included respectively for modified intention-to-treat analysis. The median age was 66 years, and the median NIHSS score at baseline was 12. The changes in cerebral infarct volume at day 14 were 0.3 mL and 0.4 mL in the ANP and placebo groups, respectively (median difference: -7.1 mL; interquartile range [IQR]: -18.3 to 2.3 mL, P = 0.30). The changes in cerebral edema volume of the ANP and placebo groups on day 14 were 11.4 mL and 4.0 mL, respectively (median difference: 3.0 mL, IQR: -1.3 to 9.9 mL, P = 0.15). The rates of SAE within 90 days were similar in the ANP (3/57, 5%) and placebo (7/60, 12%) groups (P = 0.36). Changes in serum mercury and arsenic concentrations were comparable. In patients with large artery atherosclerosis, ANP reduced the cerebral infarct volume at 14 days (median difference: -12.3 mL; IQR: -27.7 to -0.3 mL, P = 0.03).</p><p><strong>Conclusions: </strong>ANP showed a similar safety profile to placebo and non-significant tendency to reduce cerebral infarct volume in patients with moderate-to-severe stroke. Further studies are warranted to assess the efficacy of ANP in reducing cerebral infarcts and improving clinical prognosis.</p><p><strong>Trail registration: </strong>Clinicaltrials.gov, No. NCT04475328.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growing burden of inflammatory bowel disease in China: Findings from the Global Burden of Diseases 2021 and predictions to 2035. 中国炎症性肠病的负担日益加重:2021 年全球疾病负担》的研究结果及对 2035 年的预测。
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003345
Ziqing Yu, Gechong Ruan, Xiaoyin Bai, Yinghao Sun, Hong Yang, Jiaming Qian
{"title":"Growing burden of inflammatory bowel disease in China: Findings from the Global Burden of Diseases 2021 and predictions to 2035.","authors":"Ziqing Yu, Gechong Ruan, Xiaoyin Bai, Yinghao Sun, Hong Yang, Jiaming Qian","doi":"10.1097/CM9.0000000000003345","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003345","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD) imposes a significant economic and social burden in China. We aim to assess the epidemiological trends of IBD in China, and to predict the burden in the near future.</p><p><strong>Methods: </strong>The incidence, mortality, prevalence, and disability-adjusted life year (DALYs) of IBD from 1990 to 2021 were obtained from Global Burden of Disease 2021. Estimated annual percentage change (EAPC), average annual percent change, total percent change, and age-period-cohort model were used to access trends. Bayesian age-period-cohort model was utilized to predict the risk of incidence and mortality.</p><p><strong>Results: </strong>In 2021, IBD affected 168,077 people in China, with 24,941 new cases and 5640 deaths. The age-standardized rate (ASR) of incidence and death was 1.4 and 0.3, respectively. The incidence and prevalence in China were lower than the global and high socio-demographic index (SDI) regions, but the ASR of incidence and prevalence (EAPC: 2.93 and 2.54, respectively) had rapidly increased from 1990 to 2021. The ASR of death and DALYs had significantly decreased (EAPC: -3.05 and -2.93, respectively). Middle-aged and elderly populations faced a severe burden of incidence and prevalence, while the elderly population faced a severe mortality burden. It is projected that by 2035, the ASR of incidence will continue to rise, whereas the death rate will continue to decline.</p><p><strong>Conclusions: </strong>The burden of IBD in China is serious and increasingly severe. Establishing a comprehensive disease management system in China will help better control the medical burden of IBD.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Body mass index and prognostic outcomes after transcatheter aortic valve replacement: Insights from the Chinese Cardiovascular Association Database-National Transcatheter Valve Therapeutics Registry. 体重指数与经导管主动脉瓣置换术后的预后结果:中国心血管协会数据库--全国经导管瓣膜治疗登记的启示。
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003347
Qiong Liu, Sanjay Jaiswal, Qifeng Zhu, Jianfang Luo, Yan Wang, Daxin Zhou, Mao Chen, Xianbao Liu, Jian'an Wang
{"title":"Body mass index and prognostic outcomes after transcatheter aortic valve replacement: Insights from the Chinese Cardiovascular Association Database-National Transcatheter Valve Therapeutics Registry.","authors":"Qiong Liu, Sanjay Jaiswal, Qifeng Zhu, Jianfang Luo, Yan Wang, Daxin Zhou, Mao Chen, Xianbao Liu, Jian'an Wang","doi":"10.1097/CM9.0000000000003347","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003347","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142580992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ocular biometric characteristics of young Chinese people with axial lengths greater than 26.00 mm. 轴长大于 26.00 毫米的中国年轻人的眼部生物特征。
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003323
Xiaoying Zhu, Xinxin Li, Hui Yao, Xuejun Fang, Qingsong Zhang, Jihong Zhou, Jinfeng Cai, Zheng Wang, Chunli Huang, Wenjuan Wang, Shaowei Li
{"title":"Ocular biometric characteristics of young Chinese people with axial lengths greater than 26.00 mm.","authors":"Xiaoying Zhu, Xinxin Li, Hui Yao, Xuejun Fang, Qingsong Zhang, Jihong Zhou, Jinfeng Cai, Zheng Wang, Chunli Huang, Wenjuan Wang, Shaowei Li","doi":"10.1097/CM9.0000000000003323","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003323","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chest computed tomography-based artificial intelligence-aided latent class analysis for diagnosis of severe pneumonia. 基于胸部计算机断层扫描的人工智能辅助潜类分析用于重症肺炎诊断。
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003226
Caiting Chu, Yiran Guo, Zhenghai Lu, Ting Gui, Shuhui Zhao, Xuee Cui, Siwei Lu, Meijiao Jiang, Wenhua Li, Chengjin Gao
{"title":"Chest computed tomography-based artificial intelligence-aided latent class analysis for diagnosis of severe pneumonia.","authors":"Caiting Chu, Yiran Guo, Zhenghai Lu, Ting Gui, Shuhui Zhao, Xuee Cui, Siwei Lu, Meijiao Jiang, Wenhua Li, Chengjin Gao","doi":"10.1097/CM9.0000000000003226","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003226","url":null,"abstract":"<p><strong>Background: </strong>There is little literature describing the artificial intelligence (AI)-aided diagnosis of severe pneumonia (SP) subphenotypes and the association of the subphenotypes with the ventilatory treatment efficacy. The aim of our study is to illustrate whether clinical and biological heterogeneity, such as ventilation and gas-exchange, exists among patients with SP using chest computed tomography (CT)-based AI-aided latent class analysis (LCA).</p><p><strong>Methods: </strong>This retrospective study included 413 patients hospitalized at Xinhua hospital diagnosed with SP from June 1, 2015 to May 30, 2020. AI quantification results of chest CT and their combination with additional clinical variables were used to develop LCA models in an SP population. The optimal subphenotypes were determined though evaluating statistical indicators of all the LCA models, and clinical implications of them such as guiding ventilation strategies were further explored by statistical methods.</p><p><strong>Results: </strong>The two-class LCA model based on AI quantification results of chest CT can describe the biological characteristics of the SP population well and hence yielded the two clinical subphenotypes. Patients with subphenotype-1 had milder infections (P <0.001) than patients with subphenotype-2 and had lower 30-day (P <0.001) and 90-day (P <0.001) mortality, and lower in-hospital (P = 0.001) and 2-year (P <0.001) mortality. Patients with subphenotype-1 showed a better match between the percentage of non-infected lung volume (used to quantify ventilation) and oxygen saturation (used to reflect gas exchange), compared with patients with subphenotype-2. There were significant differences in the matching degree of lung ventilation and gas exchange between the two subphenotypes (P <0.001). Compared with patients with subphenotype-2, those with subphenotype-1 showed a relatively better match between CT-based AI metrics of the non-infected region and oxygenation, and their clinical outcomes were effectively improved after receiving invasive ventilation treatment.</p><p><strong>Conclusions: </strong>A two-class LCA model based on AI quantification results of chest CT in the SP population particularly revealed clinical heterogeneity of lung function. Identifying the degree of match between ventilation and gas-exchange may help guide decisions about assisted ventilation.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142580994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut microbiota and Parkinson's disease. 肠道微生物群与帕金森病
IF 7.5 3区 医学
Chinese Medical Journal Pub Date : 2024-11-06 DOI: 10.1097/CM9.0000000000003318
Lin Wang, Ying Cui, Bingyu Han, Yitong Du, Kenish Sirajbhai Salewala, Shiya Wang, Wenlu Zhao, Hongxin Zhang, Sichen Wang, Xinran Xu, Jianpeng Ma, Yan Zhu, Houzhen Tuo
{"title":"Gut microbiota and Parkinson's disease.","authors":"Lin Wang, Ying Cui, Bingyu Han, Yitong Du, Kenish Sirajbhai Salewala, Shiya Wang, Wenlu Zhao, Hongxin Zhang, Sichen Wang, Xinran Xu, Jianpeng Ma, Yan Zhu, Houzhen Tuo","doi":"10.1097/CM9.0000000000003318","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003318","url":null,"abstract":"<p><strong>Abstract: </strong>Emerging evidence suggests that dysbiosis of the gut microbiota is associated with the pathogenesis of Parkinson's disease (PD), a prevalent neurodegenerative disorder. The microbiota-gut-brain axis plays a crucial role in the development and progression of PD, and numerous studies have demonstrated the potential therapeutic benefits of modulations in the intestinal microbiota. This review provides insights into the characterization of the gut microbiota in patients with PD and highlights associations with clinical symptoms and underlying mechanisms. The discussion underscores the increased influence of the gut microbiota in the pathogenesis of PD. While the relationship is not fully elucidated, existing research demonstrates a strong correlation between changes in the composition of gut microbiota and disease development, and further investigation is warranted to explain the specific underlying mechanisms.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信